Treatment of neurodegenerative disorders, including Niemann-Pick disease type C, GM2 gangliosidosis, GM1 gangliosidosis and ataxia-telangiectasia (A-T)
Brite
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Levacetylleucine
D12967 Levacetylleucine (USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12967
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12967